Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?

Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and affects a considerable proportion of the general population worldwide. Obesity is a major risk factor for development and progression of NAFLD and weight loss is an effective intervention for the management of NAFLD....

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2022-09, Vol.13, p.984041
Main Authors: Tsankof, Alexandra, Neokosmidis, Georgios, Koureta, Evgenia, Veneti, Stavroula, Cholongitas, Evangelos, Tziomalos, Konstantinos
Format: Article
Language:English
Subjects:
Anti-Obesity Agents - therapeutic use
Diabetes Mellitus, Type 2 - epidemiology
Endocrinology
Glucagon-Like Peptide-1 Receptor
Humans
Liraglutide
lorcaserin
Non-alcoholic Fatty Liver Disease - complications
Non-alcoholic Fatty Liver Disease - drug therapy
Non-alcoholic Fatty Liver Disease - epidemiology
nonalcoholic fatty liver disease
obesity
Obesity - complications
Obesity - drug therapy
orlistat
Platelet Aggregation Inhibitors
semaglutide
Transaminases
Weight Loss
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and affects a considerable proportion of the general population worldwide. Obesity is a major risk factor for development and progression of NAFLD and weight loss is an effective intervention for the management of NAFLD. However, few patients achieve substantial and sustained weight loss with lifestyle measures. Therefore, antiobesity agents are frequently considered in patients with NAFLD but there are limited data on their safety and efficacy. In the present review, we discuss the role of antiobesity agents in the management of NAFLD. All approved antiobesity agents appear to reduce transaminase levels and to improve steatosis in patients with NAFLD. However, their effects on fibrosis are less well studied and whether they affect liver-related outcomes, including progression to cirrhosis and hepatocellular cancer, is unknown. The glucagon-like peptide-1 receptor agonists, liraglutide and semaglutide, appear to represent a first-line option in obese patients with NAFLD and type 2 diabetes mellitus (T2DM) since they induce considerable weight loss and have been extensively studied in patients with T2DM. However, more studies are needed to evaluated their effects on liver-related and cardiovascular outcomes in patients with NAFLD, particularly in those without T2DM.
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2022.984041